{"title": "Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia", "doi": "10.1101/2020.02.25.20025643", "citation_id": "2020.02.25.20025643v1", "date": "2020-02-27", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.25.20025643", "abstract": "<p>Aim: The new coronavirus pneumonia (COVID-19) outbreaking at the end of 2019 is highly contagious. Crude mortality rate reached 49% in critical patients. Inflammation matters on disease progression. This study analyzed blood inflammation indicators among mild, severe and critical patients, helping to identify severe or critical patients early.\nMethods: In this cross-sectional study, 100 patients were included and divided to mild, severe or critical groups. Correlation of peripheral blood inflammation-related indicators with disease criticality was analyzed. Cut-off values for critically ill patients were speculated through the ROC curve.\nResults\uff1aSignificantly, disease severity were associated with age (R=-0.564, P&lt;0.001), interleukin-2 receptor (IL2R) (R=-0.534, P&lt;0.001), interleukin-6 (IL-6) (R=-0.535, P&lt;0.001), interleukin-8 (IL-8) (R=-0.308, P&lt;0.001), interleukin-10 (IL-10) (R=-0.422, P&lt;0.001), tumor necrosis factor \u03b1 (TNF\u03b1) (R=-0.322, P&lt;0.001), C-reactive protein (CRP) (R=-0.604, P&lt;0.001), ferroprotein (R=-0.508, P&lt;0.001), procalcitonin (R=-0.650, P&lt;0.001), white cell counts (WBC) (R=-0.54, P&lt;0.001), lymphocyte counts (LC) (R=-0.56, P&lt;0.001), neutrophil count (NC) (R=-0.585, P&lt;0.001) and eosinophil counts (EC) (R=-0.299, P=0.01).\nConclusion\uff1aWith following parameters such as age &gt;67.5 years, IL2R &gt;793.5U/mL, CRP &gt;30.7ng/mL, ferroprotein &gt;2252\u03bcg/L, WBC&gt;9.5*10^9/L or NC &gt;7.305*10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented. Inflammation is closely related to severity of COVID-19, and IL-6, TNF\u03b1 and IL-8 might be promising therapeutic targets.</p>", "twitter_description": "Aim: The new coronavirus pneumonia (COVID-19) outbreaking at the end of 2019 is highly contagious. Crude mortality rate reached 49% in critical patients. Inflammation matters on disease progression. This study analyzed blood inflammation indicators among mild, severe and critical patients, helping to identify severe or critical patients early. Methods: In this cross-sectional study, 100 patients were included and divided to mild, severe or critical groups. Correlation of peripheral blood inflammation-related indicators with disease criticality was analyzed. Cut-off values for critically ill patients were speculated through the ROC curve. Results\uff1aSignificantly, disease severity were associated with age (R=-0.564, P<0.001), interleukin-2 receptor (IL2R) (R=-0.534, P<0.001), interleukin-6 (IL-6) (R=-0.535, P<0.001), interleukin-8 (IL-8) (R=-0.308, P<0.001), interleukin-10 (IL-10) (R=-0.422, P<0.001), tumor necrosis factor \u03b1 (TNF\u03b1) (R=-0.322, P<0.001), C-reactive protein (CRP) (R=-0.604, P<0.001), ferroprotein (R=-0.508, P<0.001), procalcitonin (R=-0.650, P<0.001), white cell counts (WBC) (R=-0.54, P<0.001), lymphocyte counts (LC) (R=-0.56, P<0.001), neutrophil count (NC) (R=-0.585, P<0.001) and eosinophil counts (EC) (R=-0.299, P=0.01). Conclusion\uff1aWith following parameters such as age >67.5 years, IL2R >793.5U/mL, CRP >30.7ng/mL, ferroprotein >2252\u03bcg/L, WBC>9.5*10^9/L or NC >7.305*10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented. Inflammation is closely related to severity of COVID-19, and IL-6, TNF\u03b1 and IL-8 might be promising therapeutic targets.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nThis study is supported by the National Natural Science Foundation of China (81904158, 81874382 and 81974567).\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.25.20025643v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.25.20025643v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.25.20025643v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/27/2020.02.25.20025643.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.25.20025643v1", "access_rights": "restricted", "authors": ["Jing Gong", "Hui Dong", "Song Qing Xia", "Yi Zhao Huang", "Dingkun Wang", "Yan Zhao", "Wenhua Liu", "Shenghao Tu", "Mingmin Zhang", "Qi Wang", "Fuer Lu"]}